NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix (Euronext: NANO, Nasdaq: NBTX) reported its outstanding shares on May 31, 2022, totaling 34,875,872. The total number of gross voting rights reached 36,393,442, while the net voting rights stood at 36,373,830. This update aligns with regulatory requirements set by the French Financial Markets Authority. As a late-stage clinical biotechnology firm, Nanobiotix focuses on developing innovative therapies for solid tumors, particularly in head and neck cancers, utilizing its proprietary nanoparticle platform.

Positive

• Nanobiotix is advancing its pipeline of therapies aimed at improving treatment outcomes for cancer patients.
• The company reported a significant number of outstanding shares and voting rights, indicating active shareholder engagement.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
May 31, 2022	34,875,872	36,393,442	36,373,830

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005920/en/

Nanobiotix



Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com



Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com



Media Relations



France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

US – Porter Novelli

Caitlin Hunt

+1 (781) 985-5967

Caitlin.hunt@porternovelli.com

Source: Nanobiotix

FAQ

What are the latest outstanding shares for Nanobiotix (NBTX)?

As of May 31, 2022, Nanobiotix has 34,875,872 outstanding shares.

What is the gross total voting rights for Nanobiotix (NBTX) as of May 31, 2022?

The gross total voting rights for Nanobiotix as of May 31, 2022, is 36,393,442.

What is the net total voting rights for Nanobiotix (NBTX) on May 31, 2022?

The net total voting rights for Nanobiotix on May 31, 2022, amounts to 36,373,830.

What is the focus of Nanobiotix in their clinical development?

Nanobiotix is focused on developing therapies for solid tumors, with an emphasis on head and neck cancers.